193 related articles for article (PubMed ID: 17647195)
1. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
[TBL] [Abstract][Full Text] [Related]
2. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
Chia SY; Thike AA; Cheok PY; Tan PH
Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
[TBL] [Abstract][Full Text] [Related]
3. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
[TBL] [Abstract][Full Text] [Related]
4. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
5. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
Bhargava R; Beriwal S; Dabbs DJ
Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
[TBL] [Abstract][Full Text] [Related]
6. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin.
Lewis GH; Subhawong AP; Nassar H; Vang R; Illei PB; Park BH; Argani P
Am J Clin Pathol; 2011 Apr; 135(4):587-91. PubMed ID: 21411781
[TBL] [Abstract][Full Text] [Related]
7. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas.
Luo MH; Huang YH; Ni YB; Tsang JY; Chan SK; Shao MM; Tse GM
Hum Pathol; 2013 Jul; 44(7):1241-50. PubMed ID: 23332923
[TBL] [Abstract][Full Text] [Related]
8. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
Wendroth SM; Mentrikoski MJ; Wick MR
Ann Diagn Pathol; 2015 Feb; 19(1):6-9. PubMed ID: 25544392
[TBL] [Abstract][Full Text] [Related]
9. Markers of metastatic carcinoma of breast origin.
Gown AM; Fulton RS; Kandalaft PL
Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens.
Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC
Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055
[TBL] [Abstract][Full Text] [Related]
11. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
[TBL] [Abstract][Full Text] [Related]
12. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
[TBL] [Abstract][Full Text] [Related]
13. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
14. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. Disseminated tumor cells in bone marrow assessed by TWIST1, cytokeratin 19, and mammaglobin A mRNA predict clinical outcome in operable breast cancer patients.
Tjensvoll K; Oltedal S; Farmen RK; Shammas FV; Heikkilä R; Kvaløy JT; Gilje B; Smaaland R; Nordgård O
Clin Breast Cancer; 2010 Oct; 10(5):378-84. PubMed ID: 20920982
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
18. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study.
Raju U; Ma CK; Shaw A
Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR.
Radhi JM
Histopathology; 2000 Feb; 36(2):156-60. PubMed ID: 10672061
[TBL] [Abstract][Full Text] [Related]
20. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
